徐秋平

    【摘要】 目的：研究卡瑞利珠單抗与化疗联用对经载药微球-肝动脉化疗栓塞(D-TACE)后病情恶化肝癌患者的效果，以期为该类患者提供安全有效的治疗方案。方法：选取2020年1月-2022年1月丰城市人民医院接收的94例经D-TACE后病情恶化肝癌患者。以单双数字法将其分作单抗组47例及化疗组47例。化疗组开展单纯化疗，单抗组则在化疗的基础上增用卡瑞利珠单抗治疗。分析两组临床疗效、肝功能、血清肿瘤标志物水平及不良反应。结果：在疾病控制率(DCR)方面对比，单抗组高于化疗组(78.72% vs. 57.45%)(P0.05)。结论：卡瑞利珠单抗联合化疗可提高D-TACE后进展的肝癌患者临床疗效，具有一定安全性，应用价值良好。

    【关键词】 肝癌 载药微球-肝动脉化疗栓塞 卡瑞利珠单抗

    Effect of Carrilizumab Combined with Chemotherapy on Patients with Advanced Liver Cancer after D-TACE/XU Qiuping. //Medical Innovation of China， 2023， 20(12)： 0-046

    [Abstract] Objective： To study the effect of Carrelizumab combined with chemotherapy on liver cancer patients with worsening disease after drug-loaded microspheres-transcatheter arterial chemoembolization (D-TACE)， so as to provide a safe and effective treatment plan for these patients. Method： A total of 94 patients with liver cancer whose condition worsened after D-TACE in Fengcheng People's Hospital from January 2020 to January 2022 were selected ......